Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words '7-36 AMIDE' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 245 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Duhlmeier, R; Deegen, E; Fuhrmann, H; Widdel, A; Sallmann, HP
      Glucose-dependent insulinotropic polypeptide (GIP) and the enteroinsular axis in equines (Equus caballus)

      COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR AND INTEGRATIVE PHYSIOLOGY
    2. Meneilly, GS; McIntosh, CHS; Pederson, RA; Habener, JF; Gingerich, R; Egan, JM; Elahi, D
      Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake inelderly patients with diabetes

      JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
    3. Vara, E; Arias-Diaz, J; Garcia, C; Balibrea, JL; Blazquez, E
      Glucagon-like peptide-1(7-34) amide stimulates surfactant secretion in human type II pneumocytes

      AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
    4. Creutzfeldt, W
      The entero-insular axis in type 2 diabetes - incretins as therapeutic agents

      EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    5. Wettergren, A
      Glucagon-like peptide-1 - Gastrointestinal function and possible mechanismof action

      DANISH MEDICAL BULLETIN
    6. Guenifi, A; Ahren, B; Abdel-Halim, SM
      Differential effects of glucagon-like peptide-1 (7-36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro

      PANCREAS
    7. Knudsen, LB; Agerso, H; Bjenning, C; Bregenholt, S; Carr, RD; Godtfredsen, C; Holst, JJ; Huusfeldt, PO; Larsen, MO; Larsen, PJ; Nielsen, PF; Ribel, U; Rolin, B; Romer, J; Sturis, J; Wilken, M; Kristensen, P
      GLP-1 derivatives as novel compounds for the treatment of type 2 diabetes:selection of NN2211 for clinical development

      DRUGS OF THE FUTURE
    8. Parkes, D; Jodka, C; Smith, P; Nayak, S; Rinehart, L; Gingerich, R; Chen, K; Young, A
      Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1

      DRUG DEVELOPMENT RESEARCH
    9. O'Harte, FPM; Mooney, MH; Kelly, CMN; McKillop, AM; Flatt, PR
      Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice

      REGULATORY PEPTIDES
    10. Moro, F; Levenez, F; Durual, S; Plaisancie, P; Thim, L; Giraud, AS; Cuber, JC
      Secretion of the trefoil factor TFF3 from the isolated vascularly perfusedrat colon

      REGULATORY PEPTIDES
    11. Larsen, J; Hylleberg, B; Ng, K; Damsbo, P
      Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtainacceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment

      DIABETES CARE
    12. Holst, JJ; Orskov, C
      Incretin hormones - an update

      SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION
    13. Choi, YH; Anderson, GH
      An interaction between hypothalamic glucagon-like peptide-1 and macronutrient composition determines food intake in rats

      JOURNAL OF NUTRITION
    14. Toft-Nielsen, MB; Damholt, MB; Madsbad, S; Hilsted, LM; Hughes, TE; Michelsen, BK; Holst, JJ
      Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

      JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    15. Toft-Nielsen, MB; Madsbad, S; Holst, JJ
      Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

      JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    16. Bertin, E; Arner, P; Bolinder, J; Hagstrom-Toft, E
      Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo

      JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    17. Lovshin, J; Estall, J; Yusta, B; Brown, TJ; Drucker, DJ
      Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling

      JOURNAL OF BIOLOGICAL CHEMISTRY
    18. Villanueva-Penacarrillo, ML; Marquez, L; Gonzalez, N; Diaz-Miguel, M; Valverde, I
      Effect of GLP-1 on lipid metabolism in human adipocytes

      HORMONE AND METABOLIC RESEARCH
    19. Ranganath, LR; Beety, JM; Wright, J; Morgan, LM
      Nutrient regulation of post-heparin lipoprotein lipase activity in obese subjects

      HORMONE AND METABOLIC RESEARCH
    20. Garcia-Flores, M; Zueco, JA; Alvarez, E; Blazquez, E
      Expression of glucagon-like peptide-1 (GLP-1) receptor and the effect of GLP-1-(7-36) amide on insulin release by pancreatic islets during rat ontogenic development

      EUROPEAN JOURNAL OF BIOCHEMISTRY
    21. Rocca, AS; LaGreca, J; Kalitsky, J; Brubaker, PL
      Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1

      ENDOCRINOLOGY
    22. Drucker, DJ
      Minireview: The glucagon-like peptides

      ENDOCRINOLOGY
    23. Lynn, FC; Pamir, N; Ng, EHC; McIntosh, CHS; Kieffer, TJ; Pederson, RA
      Defective glucose-dependent insulinotropic polypeptide receptor expressionin diabetic fatty Zucker rats

      DIABETES
    24. Ritzel, R; Schulte, M; Porksen, N; Nauck, MS; Holst, JJ; Juhl, C; Marz, W; Schmitz, O; Schmiegel, WH; Nauck, MA
      Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance

      DIABETES
    25. Meier, JJ; Huking, K; Holst, JJ; Deacon, CF; Schmiegel, WH; Nauck, MA
      Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes

      DIABETES
    26. Larsen, PJ; Fledelius, C; Knudsen, LB; Tang-Christensen, M
      Systemic administration of the long-acting GLP-1 derivative NN2211 induceslasting and reversible weight loss in both normal and obese rats

      DIABETES
    27. Nagakura, T; Yasuda, N; Yamazaki, K; Ikuta, H; Yoshikawa, S; Asano, O; Tanaka, I
      Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient fischer rats

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

    28. Novel N-substituted-2-cyanopyrrolidines as potent inhibitors of dipeptidylpeptidase IV in the treatment of non-insulin-dependent diabetes mellitus

      EXPERT OPINION ON THERAPEUTIC PATENTS
    29. D'Alessio, D
      Glucagon-like peptide 1 (GLP-1) in diabetes and aging

      JOURNAL OF ANTI-AGING MEDICINE
    30. Nauck, M; Hahn, S; Sauerwald, A; Schmiegel, W
      Lack of germline mutations in the preproglucagon gene region coding for glucagon-like peptide 1 in Type 2 diabetic (NIDDM) patients

      EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    31. Hedetoft, C; Sheikh, SP; Larsen, S; Holst, JJ
      Effect of glucagon-like peptide 1(7-36)amide in insulin-treated patients with diabetes mellitus secondary to chronic pancreatitis

      PANCREAS
    32. Perfetti, R; Merkel, P
      Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function

      EUROPEAN JOURNAL OF ENDOCRINOLOGY
    33. Flint, A; Raben, A; Rehfeld, JF; Holst, JJ; Astrup, A
      The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans

      INTERNATIONAL JOURNAL OF OBESITY
    34. O'Harte, FPM; Mooney, MH; Lawlor, A; Flatt, PR
      N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo

      BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
    35. Katschinski, M
      Nutritional implications of cephalic phase gastrointestinal responses

      APPETITE
    36. Ebinger, M; Jehle, DR; Fussgaenger, RD; Fehmann, HC; Jehle, PM
      Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes

      AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
    37. Vilsboll, T; Toft-Nielsen, MB; Krarup, T; Madsbad, S; Dinesen, B; Holst, JJ
      Evaluation of beta-cell secretory capacity using glucagon-like peptide 1

      DIABETES CARE
    38. Hoentjen, F; Hopman, WPM; Maas, MIM; Jansen, JBMJ
      Role of circulating peptide YY in the inhibition of gastric acid secretionby dietary fat in humans

      SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
    39. de Fonseca, FR; Navarro, M; Alvarez, E; Roncero, I; Chowen, JA; Maestre, O; Gomez, R; Munoz, RM; Eng, J; Blazquez, E
      Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats

      METABOLISM-CLINICAL AND EXPERIMENTAL
    40. Yip, RGC; Wolfe, MM
      GIP biology and fat metabolism

      LIFE SCIENCES
    41. Knudsen, LB; Nielsen, PF; Huusfeldt, PO; Johansen, NL; Madsen, K; Pedersen, FZ; Thogersen, H; Wilken, M; Agerso, H
      Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

      JOURNAL OF MEDICINAL CHEMISTRY
    42. O'Harte, FPM; Mooney, MH; Kelly, CMN; Flatt, PR
      Improved glycaemic control in obese diabetic ob/ob mice using N-terminallymodified gastric inhibitory polypeptide

      JOURNAL OF ENDOCRINOLOGY
    43. Siegel, EG; Seidenstucker, A; Gallwitz, B; Schmitz, F; Reinecke-Luthge, A; Kloppel, G; Folsch, UR; Schmidt, WE
      Insulin secretion defects in liver cirrhosis can be reversed by glucagon-like peptide-1

      JOURNAL OF ENDOCRINOLOGY
    44. Lugari, R; Dell'Anna, C; Ugolotti, D; Dei Cas, A; Barilli, AL; Zandomeneghi, R; Marani, B; Lotti, M; Orlandini, A; Gnudi, A
      Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes

      HORMONE AND METABOLIC RESEARCH
    45. Moro, F; Levenez, F; Nemoz-Gaillard, E; Pellissier, S; Plaisancie, P; Cuber, JC
      Release of guanylin immunoreactivity from the isolated vascularly perfusedrat colon

      ENDOCRINOLOGY
    46. Fritsche, A; Stefan, N; Hardt, E; Haring, H; Stumvoll, M
      Characterisation of beta-cell dysfunction of impaired glucose tolerance: Evidence for impairment of incretin-induced insulin secretion

      DIABETOLOGIA
    47. Scrocchi, LA; Hill, ME; Saleh, J; Perkins, B; Drucker, DJ
      Elimination of glucagon-like peptide 1R signaling does not modify weight gain and islet adaptation in mice with combined disruption of leptin and GLP-1 action

      DIABETES
    48. Mojsov, S
      Glucagon-like peptide-1 (GLP-1) and the control of glucose metabolism in mammals and teleost fish

      AMERICAN ZOOLOGIST
    49. Brynes, AE; Edwards, CM; Jadhav, A; Ghatei, MA; Bloom, SR; Frost, GS
      Diet-induced change in fatty acid composition of plasma triacylglycerols is not associated with change in glucagon-like peptide 1 or insulin sensitivity in people with type 2 diabetes

      AMERICAN JOURNAL OF CLINICAL NUTRITION
    50. Jackson, KG; Zampelas, A; Knapper, JME; Roche, HM; Gibney, MJ; Kafatos, A; Gould, BJ; Wright, JW; Williams, CM
      Differences in glucose-dependent insulinotrophic polypeptide hormone and hepatic lipase in subjects of southern and northern Europe: implications forpostprandial lipemia

      AMERICAN JOURNAL OF CLINICAL NUTRITION
    51. Caro, J; Wishner, KL
      Research advances in the treatment of type 2 diabetes mellitus

      INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
    52. Holst, JJ
      Glucagon-like peptide 1 (GLP-1): An intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential

      TRENDS IN ENDOCRINOLOGY AND METABOLISM
    53. Hassan, M; Eskilsson, A; Nilsson, C; Jonsson, C; Jacobsson, H; Refai, E; Larsson, S; Efendic, S
      In vivo dynamic distribution of I-131-glucagon-like peptide-1 (7-36) amidein the rat studied by gamma camera

      NUCLEAR MEDICINE AND BIOLOGY
    54. Holst, JJ
      Glucagon-like peptide-1, a gastrointestinal hormone with a pharmaceutical potential

      CURRENT MEDICINAL CHEMISTRY
    55. Ahren, B; Pacini, G
      Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice

      AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
    56. Barragan, JM; Eng, J; Rodriguez, R; Blazquez, E
      Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats

      AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
    57. Siegel, EG; Gallwitz, B; Scharf, G; Mentlein, R; Morys-Wortmann, C; Folsch, UR; Schrezenmeir, J; Drescher, K; Schmidt, WE
      Biological activity of GLP-1-analogues with N-terminal modifications

      REGULATORY PEPTIDES
    58. Toft-Nielsen, MB; Madsbad, S; Holst, JJ
      Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients

      DIABETES CARE
    59. Anini, Y; Fu-Cheng, XM; Cuber, JC; Kervran, A; Chariot, J; Roze, C
      Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat

      PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
    60. Meurer, JA; Colca, JR; Burton, PS; Elhammer, AP
      Properties of native and in vitro glycosylated forms of the glucagon-like peptide-1 receptor antagonist exendin(9-39)

      METABOLISM-CLINICAL AND EXPERIMENTAL
    61. Burcelin, R; Dolci, W; Thorens, B
      Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1

      METABOLISM-CLINICAL AND EXPERIMENTAL
    62. Freyse, EJ; Knospe, S; Becher, T; El Hag, O; Goke, B; Fischer, U
      Glucagon-like peptide-1 has no insulin-like effects in insulin-dependent diabetic dogs maintained normoglycemic and normoinsulinemic

      METABOLISM-CLINICAL AND EXPERIMENTAL
    63. Deacon, CF; Holst, JJ; Carr, RD
      Glucagon-like peptide-1: A basis for new approaches to the management of diabetes

      DRUGS OF TODAY
    64. Claustre, J; Brechet, S; Plaisancie, P; Chayvialle, JA; Cuber, JC
      Stimulatory effect of beta-adrenergic agonists on ileal L cell secretion and modulation by alpha-adrenergic activation

      JOURNAL OF ENDOCRINOLOGY
    65. Holz, GG; Leech, CA; Heller, RS; Castonguay, M; Habener, JF
      cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells - A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37)

      JOURNAL OF BIOLOGICAL CHEMISTRY
    66. Gutzwiller, JP; Goke, B; Drewe, J; Hildebrand, P; Ketterer, S; Handschin, D; Winterhalder, R; Conen, D; Beglinger, C
      Glucagon-like peptide-1: a potent regulator of food intake in humans

      GUT
    67. Meeran, K; O'Shea, D; Edwards, CMB; Turton, MD; Heath, MM; Gunn, I; Abusnana, S; Rossi, M; Small, CJ; Goldstone, AP; Taylor, GM; Sunter, D; Steere, J; Choi, SJ; Ghatei, MA; Bloom, SR
      Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat

      ENDOCRINOLOGY
    68. Nauck, MA
      Is glucagon-like peptide 1 an incretin hormone?

      DIABETOLOGIA
    69. Sandhu, H; Wiesenthal, SR; MacDonald, PE; McCall, RH; Tchipashvili, V; Rashid, S; Satkunarajah, M; Irwin, DM; Shi, ZQ; Brubaker, PL; Wheeler, MB; Vranic, M; Efendic, S; Giacca, A
      Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs

      DIABETES
    70. O'Harte, FPM; Mooney, MH; Flatt, PR
      NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity

      DIABETES
    71. Long, SJ; Sutton, JA; Amaee, WB; Giouvanoudi, A; Spyrou, NM; Rogers, PJ; Morgan, LV
      No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man

      BRITISH JOURNAL OF NUTRITION
    72. Hiroyoshi, M; Tateishi, K; Yasunami, Y; Maeshiro, K; Ono, J; Matsuoka, Y; Ikeda, S
      Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes

      AMERICAN JOURNAL OF GASTROENTEROLOGY
    73. ROSSELIN G; LECLERCQMEYER V; BOISSART C; PESSAH M; MALAISSE WJ
      GLP-1 RECEPTORS IN GOLDEN SYRIAN-HAMSTER ISLETS - IDENTIFICATION AND FUNCTIONAL-CHARACTERIZATION

      ENDOCRINE
    74. WILLMS B; IDOWU K; HOLST JJ; CREUTZFELDT W; NAUCK MA
      OVERNIGHT GLP-1 NORMALIZES FASTING BUT NOT DAYTIME PLASMA-GLUCOSE LEVELS IN NIDDM PATIENTS

      EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
    75. NAUCK MA
      GLUCAGON-LIKE-PEPTIDE-1 (GLP-1) - A POTENT GUT HORMONE WITH A POSSIBLE THERAPEUTIC PERSPECTIVE

      Acta diabetologica
    76. HANSEN BF; JENSEN P; NEPPERCHRISTENSEN E; SKJOLSTRUP B
      EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE ON INSULIN-STIMULATED RAT SKELETAL-MUSCLE GLUCOSE-TRANSPORT

      Acta diabetologica
    77. BRYNES AE; FROST GS; EDWARDS MB; GHATEL MA; BLOOM SR
      PLASMA GLUCAGON-LIKE PEPTIDE-1(7-36) AMIDE (GLP-1) RESPONSE TO LIQUID-PHASE, SOLID-PHASE, AND MEALS OF DIFFERING LIPID-COMPOSITION

      Nutrition
    78. Blazquez, E; Alvarez, E; Roncero, I; Rodriguez-Fonseca, F; Chowen, JA; Zueco, JA
      Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide

      MOLECULAR NEUROBIOLOGY
    79. FEHMANN HC; PRACHT A; GOKE B
      HIGH-LEVEL EXPRESSION OF THE GLP-I RECEPTOR RESULTS IN RECEPTOR DESENSITIZATION

      Pancreas
    80. NAITO H; SASAKI I; MATSUNO S
      SURGICAL ASPECT OF ENTEROINSULAR AXIS AFTER GASTROINTESTINAL SURGERY WITH REFERENCE TO INCRETIN SECRETION

      Pancreas
    81. PERFETTI R; BARNETT PS; MATHUR R; EGAN JM
      NOVEL THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE-2 DIABETES

      Diabetes/metabolism reviews
    82. SEIFARTH C; BERGMANN J; HOLST JJ; RITZEL R; SCHMIEGEL W; NAUCK MA
      PROLONGED AND ENHANCED SECRETION OF GLUCAGON-LIKE PEPTIDE-1 (7-36 AMIDE) AFTER ORAL SUCROSE DUE TO ALPHA-GLUCOSIDASE INHIBITION (ACARBOSE) IN TYPE-2 DIABETIC-PATIENTS

      Diabetic medicine
    83. YANG H; EGAN JM; WANG Y; MOYES CD; ROTH J; MONTROSE MH; MONTROSERAFIZADEH C
      GLP-1 ACTION IN L6 MYOTUBES IS VIA A RECEPTOR DIFFERENT FROM THE PANCREATIC GLP-1 RECEPTOR

      American journal of physiology. Cell physiology
    84. OHARTE FPM; ABDELWAHAB YHA; CONLON JM; FLATT PR
      AMINO-TERMINAL GLYCATION OF GASTRIC-INHIBITORY POLYPEPTIDE ENHANCES ITS INSULINOTROPIC ACTION ON CLONAL PANCREATIC B-CELLS

      Biochimica et biophysica acta (G). General subjects
    85. WETTERGREN A; WOJDEMANN M; HOLST JJ
      THE INHIBITORY EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE ON ANTRAL MOTILITY IS ANTAGONIZED BY ITS N-TERMINALLY TRUNCATED PRIMARY METABOLITE GLP-1 (9-36)AMIDE

      Peptides (New York, N.Y. 1980)
    86. WETTERGREN A; PRIDAL L; WOJDEMANN M; HOLST JJ
      AMIDATED AND NON-AMIDATED GLUCAGON-LIKE PEPTIDE-1 (GLP-1) - NONPANCREATIC EFFECTS (CEPHALIC PHASE ACID-SECRETION) AND STABILITY IN PLASMA IN HUMANS

      Regulatory peptides
    87. GIRALT M; VERGARA P
      SYMPATHETIC PATHWAYS MEDIATE GLP-1 ACTIONS IN THE GASTROINTESTINAL-TRACT OF THE RAT

      Regulatory peptides
    88. NAUCK MA; SAUERWALD A; RITZEL R; HOLST JJ; SCHMIEGEL W
      INFLUENCE OF GLUCAGON-LIKE PEPTIDE 1 ON FASTING GLYCEMIA IN TYPE-2 DIABETIC-PATIENTS TREATED WITH INSULIN AFTER SULFONYLUREA SECONDARY FAILURE

      Diabetes care
    89. TODD JF; EDWARDS CMB; GHATEI MA; MATHER HM; BLOOM SR
      SUBCUTANEOUS GLUCAGON-LIKE PEPTIDE-I IMPROVES POSTPRANDIAL GLYCEMIC CONTROL OVER A 3-WEEK PERIOD IN PATIENTS WITH EARLY-TYPE-2 DIABETES

      Clinical science
    90. Edwards, CMB; Todd, JF; Ghatei, MA; Bloom, SR
      Subcutaneous glucagon-like peptide-I (7-36) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects

      CLINICAL SCIENCE
    91. OHARTE FPM; GRAY AM; FLATT PR
      GASTRIC-INHIBITORY POLYPEPTIDE AND EFFECTS OF GLYCATION ON GLUCOSE-TRANSPORT AND METABOLISM IN ISOLATED MOUSE ABDOMINAL MUSCLE

      Journal of Endocrinology
    92. SCHIRRA J; LEICHT P; HILDEBRAND P; BEGLINGER C; ARNOLD R; GOKE B; KATSCHINSKI M
      MECHANISMS OF THE ANTIDIABETIC ACTION OF SUBCUTANEOUS GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE IN NON-INSULIN-DEPENDENT DIABETES-MELLITUS

      Journal of Endocrinology
    93. SCHIRRA J; STURM K; LEICHT P; ARNOLD R; GOKE B; KATSCHINSKI M
      EXENDIN(9-39)AMIDE IS AN ANTAGONIST OF GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE IN HUMANS

      The Journal of clinical investigation
    94. BEAK SA; HEATH MM; SMALL CJ; MORGAN DGA; GHATEI MA; TAYLOR AD; BUCKINGHAM JC; BLOOM SR; SMITH DM
      GLUCAGON-LIKE PEPTIDE-1 STIMULATES LUTEINIZING-HORMONE-RELEASING HORMONE-SECRETION IN A RODENT HYPOTHALAMIC NEURONAL CELL-LINE

      The Journal of clinical investigation
    95. RYAN AS; EGAN JM; HABENER JF; ELAHI D
      INSULINOTROPIC HORMONE GLUCAGON-LIKE PEPTIDE-1-(7-37) APPEARS NOT TO AUGMENT INSULIN-MEDIATED GLUCOSE-UPTAKE IN YOUNG MEN DURING EUGLYCEMIA

      The Journal of clinical endocrinology and metabolism
    96. DAMHOLT AB; BUCHAN AMJ; KOFOD H
      GLUCAGON-LIKE-PEPTIDE-1 SECRETION FROM CANINE L-CELLS IS INCREASED BYGLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE BUT UNAFFECTED BY GLUCOSE

      Endocrinology
    97. BRUBAKER PL; SCHLOOS J; DRUCKER DJ
      REGULATION OF GLUCAGON-LIKE PEPTIDE-1 SYNTHESIS AND SECRETION IN THE GLUTAG ENTEROENDOCRINE CELL-LINE

      Endocrinology
    98. PRINTZ H; REITER S; SAMADI N; EBRAHIMSADE S; KIRCHNER R; ARNOLD R; GOKE B
      GLP-1 RELEASE IN MAN AFTER LOWER LARGE-BOWEL RESECTION OR INTRARECTALGLUCOSE-ADMINISTRATION

      Digestion
    99. TOFTNIELSEN M; MADSBAD S; HOLST JJ
      EXAGGERATED SECRETION OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) COULD CAUSE REACTIVE HYPOGLYCEMIA

      Diabetologia
    100. OHARTE FPM; ABDELWAHAB YHA; CONLON JM; FLATT PR
      GLYCATION OF GLUCAGON-LIKE PEPTIDE-1(7-36)AMIDE - CHARACTERIZATION AND IMPAIRED ACTION ON RAT INSULIN-SECRETING CELLS

      Diabetologia


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 16/01/21 alle ore 19:50:55